Pure Global

Belimumab in SLE Synovial Inflammation and Lymph Nodes - Trial NCT06327724

Access comprehensive clinical trial information for NCT06327724 through Pure Global AI's free database. This phase not specified trial is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and is currently Recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06327724
Recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT06327724
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Belimumab in SLE Synovial Inflammation and Lymph Nodes
The Effects of Belimumab on Synovial Inflammation and Composition of Lymph Nodes in SLE Patients

Study Focus

Belimumab

Observational

drug

Sponsor & Location

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Amsterdam, Netherlands

Timeline & Enrollment

N/A

Sep 01, 2023

Mar 01, 2025

15 participants

Primary Outcome

Differences in lymph node cellular composition as assessed by advanced flow cytometry

Summary

Systemic lupus erythematosus (SLE)is an immune-mediated inflammatory disease (IMIDs) of which
 the cellular and molecular alterations of the immune system driving the diseases still
 remains largely unknown. Accordingly, it remains difficult to predict the individual
 patient's response to treatment. Moreover, the patient's response to treatment remains
 heterogeneous and difficult to predict, despite the development of a variety of novel and
 powerful drugs (including the so-called biologicals). Therefore, there is a clear need for
 the identification and validation of cellular and molecular biomarkers which can provide
 useful clinical information for diagnosis, classification, prognosis and treatment, as well
 as the development of new therapeutic strategies. Biomarkers can be found and analyzed in
 different body compartments, of which the peripheral blood and the intra-articular synovial
 fluid or tissue are most easily accessible. However, previous studies in RA and other IMIDs
 showed that adaptive immune responses in other tissues such as lymph nodes also play an
 important role. Investigating other immune compartments of the body such as the lymph nodes
 could result in new insights. To study the early pathogenesis of inflammatory conditions, in
 2008 our department initiated core-needle inguinal lymph node biopsy sampling. Since then
 more than 100 lymph node biopsy procedures were performed. The procedure is well-tolerated
 and, other than a small hematoma which does not require therapy in most of the cases, no
 complications were reported.
 
 In the current study, the effects of belimumab (anti-BAFF) in SLE will be investigated by
 studying the immune alterations taking place in lymph nodes in comparison to peripheral blood
 and immune alterations taking place in the end-organ, e.g. the joint (wrist, knee or ankle)
 by taking synovial biopsies during a needle- or mini-arthroscopy. This procedure has been
 performed frequently in our department over the last 15 years. In this way immune alterations
 in the lymph nodes (secondary lymphoid organ), peripheral blood (systemic) and the joint (end
 organ for the disease) will be assessed and compared.

ICD-10 Classifications

Systemic lupus erythematosus
Systemic lupus erythematosus, unspecified
Lupus erythematosus
Systemic lupus erythematosus with organ or system involvement
Other forms of systemic lupus erythematosus

Data Source

ClinicalTrials.gov

NCT06327724

Non-Device Trial